Overview

Venetoclax, development code ABT-199 and marketed as Ventok, is supplied in a 100mg*112 tablet pack and is a selective BCL-2 inhibitor used in certain leukemias and lymphomas. Its clinical value comes from restoring apoptosis in cancer cells that rely on BCL-2 to escape death. For B2B teams the more interesting story is resistance: understanding how tumors evade BCL-2 blockade explains both sequencing decisions and why the product remains a recurring line item in hematology procurement.

How It Works

Venetoclax binds the BH3 hydrophobic groove of BCL-2, displacing pro-apoptotic proteins such as BIM and triggering the mitochondrial pathway of cell death. This targeted displacement is fundamentally different from DNA-damaging therapy. The 100 mg tablet strength supports the staged titration that characterizes BCL-2 inhibitor use, where dose is ramped to manage the tumor-lysis risk tied to rapid apoptotic load. Resistance emerges when cells no longer depend on BCL-2 alone for survival.

Indications

Venetoclax is used in adults with chronic lymphocytic leukemia and certain lymphoma subtypes, frequently within combination regimens defined by local approval. Patient suitability follows the registered indication and, in some settings, biomarker or prior-therapy history. Wholesale listings should mirror the approved label of the destination market and avoid implying standalone cure claims.

Dosage & Administration

Presented as 100 mg tablets in a 112-table pack, venetoclax is initiated through a gradual dose ramp under physician supervision, with the pace set by the treatment setting and tolerability. The pack size supports the extended, titration-based schedule typical of BCL-2 inhibitor therapy. Store as labeled, away from moisture, with batch and expiry printed for traceability.

Storage & Sourcing

Produced under GMP by partners including Tlph, Everest, and AbbVie, venetoclax ships with certificate of analysis and GMP documentation. Cold-chain guidance accompanies export orders because storage conditions affect stability. MOQ and lead time are contracted per buyer, and the supplier provides the import dossier needed for hematology-product clearance.

FAQ

Q: How do tumors become resistant to venetoclax?
A: Resistance commonly arises when cells upregulate alternative anti-apoptotic proteins such as MCL-1 or acquire BCL-2 mutations that weaken inhibitor binding, reducing dependence on BCL-2.

Q: Why is venetoclax dosing ramped gradually?
A: The ramp controls the speed of tumor-cell death and the associated tumor-lysis burden, which is the main dose-limiting safety concern with BCL-2 inhibitors.

Q: Which manufacturers supply the 100mg*112 presentation?
A: The 100 mg*112 tablet pack is offered through Tlph, Everest, and AbbVie partnerships, with GMP and COA documentation provided per shipment.